The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that...

Full description

Bibliographic Details
Main Authors:	Herrington, W, Preiss, D, Haynes, R, von Eynatten, M, Staplin, N, Hauske, S, George, J, Green, J, Landray, M, Baigent, C, Wanner, C
Format:	Journal article
Published:	Oxford University Press 2018

Similar Items

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
by: Mayne, KM, et al.
Published: (2024)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
by: Mayne, K, et al.
Published: (2024)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
by: Preiss, D, et al.
Published: (2022)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
by: Herrington, W, et al.
Published: (2022)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
by: Staplin, N, et al.
Published: (2023)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
by: Judge, PK, et al.
Published: (2024)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
by: Herrington, W, et al.
Published: (2022)

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY
by: Nangaku, M, et al.
Published: (2024)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
by: Zhu, P, et al.
Published: (2020)

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
by: João Pedro Ferreira, et al.
Published: (2021-04-01)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
by: Takashi Kadowaki, et al.
Published: (2019-05-01)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
by: Herrington, WG, et al.
Published: (2023)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
by: Mayne, K, et al.
Published: (2023)

Biliary tract and liver complications in polycystic kidney disease
by: Judge, P, et al.
Published: (2017)

Neprilysin inhibition in chronic kidney disease.
by: Judge, P, et al.
Published: (2014)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
by: Schlackow, I, et al.
Published: (2017)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
by: Staplin, N, et al.
Published: (2022)

Kidney disease trials for the 21st century: innovations in design and conduct
by: Herrington, W, et al.
Published: (2019)

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
by: Staplin, N, et al.
Published: (2023)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
by: Haynes, R, et al.
Published: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
by: Haynes, R, et al.
Published: (2014)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
by: Mihaylova, B, et al.
Published: (2019)

Which cardiovascular risk factors matter in chronic kidney disease?
by: Baigent, C, et al.
Published: (2007)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)

Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
by: Samy Hadjadj, et al.
Published: (2024-03-01)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
by: Mafham, M, et al.
Published: (2017)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
by: Staplin, N, et al.
Published: (2021)

Empagliflozin in patients with chronic kidney disease
by: Herrington, WG, et al.
Published: (2022)

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors
by: Herrington, WG, et al.
Published: (2021)

Chronic kidney disease, heart failure and neprilysin inhibition
by: Haynes, R, et al.
Published: (2019)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2016)

Long-term effects of empagliflozin in patients with chronic kidney disease
by: Herrington, WG, et al.
Published: (2024)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
by: Zhu, D, et al.
Published: (2024)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
by: Reith, C, et al.
Published: (2017)

UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (sglt-2) inhibition in adults with kidney disease 2023 update
by: Roddick, AJ, et al.
Published: (2023)

The role of lipoprotein(a) in chronic kidney disease
by: Hopewell, J, et al.
Published: (2018)

Elective conversion to sirolimus vs. continued tacrolimus in kidney transplantation (the 3c study): Results of a randomized trial
by: Haynes, R, et al.
Published: (2017)

Benefits of lowering cholesterol in chronic kidney disease Reply
by: Baigent, C, et al.
Published: (2011)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
by: C. Reith, et al.
Published: (2017-05-01)